Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Blood Rheology After Allogeneic Hematopoietic Stem Cell Transplantation or Gene Therapy in Sickle Cell Disease.

Blood advances·2026
Same author

Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients.

Blood immunology & cellular therapy·2026
Same author

Controlling metal-carbonate phase, form, and function through de novo protein design.

bioRxiv : the preprint server for biology·2026
Same author

Costimulation drives CAR-T cell division fate.

Nature immunology·2026
Same author

Systems-Scale Structural Modeling Reveals the Germline Architecture of Immunodominance.

bioRxiv : the preprint server for biology·2026
Same author

Generative design of programmable asymmetric β-barrel nanopores.

bioRxiv : the preprint server for biology·2026

相关实验视频

Updated: Feb 28, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K

通过设计的生物PROTACs重新编程CAR T细胞.

Vivek S Peche, Sebastian Kenny, Tae Gun Kang

    bioRxiv : the preprint server for biology
    |February 27, 2026
    PubMed
    概括

    新的bioPROTACs提供一种可逆的非基因编辑方法来增强CAR T细胞功能. 这种方法针对T细胞耗尽调节器,为下一代细胞疗法提供可调节的策略.

    更多相关视频

    Generation of Human Chimeric Antigen Receptor Regulatory T Cells
    10:29

    Generation of Human Chimeric Antigen Receptor Regulatory T Cells

    Published on: January 3, 2025

    2.5K
    Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
    09:29

    Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

    Published on: February 1, 2013

    19.0K

    相关实验视频

    Last Updated: Feb 28, 2026

    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
    06:10

    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

    Published on: May 9, 2025

    1.0K
    Generation of Human Chimeric Antigen Receptor Regulatory T Cells
    10:29

    Generation of Human Chimeric Antigen Receptor Regulatory T Cells

    Published on: January 3, 2025

    2.5K
    Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
    09:29

    Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

    Published on: February 1, 2013

    19.0K

    科学领域:

    • 免疫学 免疫学 免疫学
    • 分子生物学分子生物学
    • 生物技术是生物技术.

    背景情况:

    • 基因编辑通过破坏负调节器来增强CAR T细胞功能.
    • 现有的基因编辑方法对治疗应用有局限性.

    研究的目的:

    • 探索新设计的向降解剂 (bioPROTACs) 作为CAR T细胞增强基因编辑的替代品.
    • 研究生物PROTACs针对DNMT3A的疗效,DNMT3A是T细胞耗尽的调节剂.

    主要方法:

    • 为CAR T细胞应用设计和生成生物PROTAC.
    • 在针对DNMT3A.的CAR T细胞中表达的生物PROTACs.
    • 评估了生物PROTAC表达对T细胞表型的功能影响.

    主要成果:

    • 针对DNMT3A的CAR T细胞中的BioPROTAC表达. 代基因淘汰效应.
    • 生物PROTAC方法展示了一个可逆和可调的策略.
    • 这种方法成功地重新编程了T细胞的命运,解决了T细胞疲劳问题.

    结论:

    • 新设计的生物PROTACs提供了一个可行的,非基因编辑替代品,用于增强CAR T细胞功能.
    • 这种可逆的方法为T细胞命运重编程提供了可调节的控制.
    • 在开发下一代细胞疗法方面,BioPROTACs具有广泛的适用性.